^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Deciphera Pharmaceuticals

    i
    Other names: Deciphera, | Deciphera
    Evidence

    News

    2years
    Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 (Businesswire)
    P3 | N=453 | INTRIGUE (NCT03673501 ) | Sponsor: Deciphera Pharmaceuticals LLC | "Deciphera Pharmaceuticals, Inc...announced that Nature Medicine has published results from a circulating tumor DNA (ctDNA) analysis of the INTRIGUE Phase 3 study of QINLOCK (ripretinib) in GIST patients with mutations in KIT exon 11 and 17/18 only previously treated with imatinib....In the AP-ITT population, QINLOCK demonstrated similar efficacy with a median progression-free survival (PFS) of 8.0 months versus 8.3 months for sunitinib (HR 1.05, nominal p=0.72). There were fewer patients with Grade 3-4 drug-related treatment emergent adverse events (TEAE) with QINLOCK (26.5%) compared with sunitinib (55.2%)."
    P3 data
    |
    Qinlock (ripretinib)